Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

888
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
888

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma.

European urology·2026
Same author

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.

Nature medicine·2026
Same author

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.

European urology·2025
Same author

High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study.

European journal of cancer (Oxford, England : 1990)·2025
Same journal

Clinical advancement in the management of mutant isocitrate dehydrogenase (<i>IDH</i>) cancers.

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]·2026
Same journal

Isocitrate dehydrogenase mutations as potential tumour agnostic targets.

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]·2026
Same journal

Use of [<sup>177</sup>Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study.

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]·2021
Same journal

Matching-adjusted indirect treatment comparison of [<sup>177</sup>Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [<sup>177</sup>Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours.

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]·2021
Same journal

Can the peptide receptor radionuclide therapy [<sup>177</sup>Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]·2021
Same journal

Rare ovarian tumours. Other treatments for ovarian cancer.

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]·2020
See all related articles

Related Experiment Video

Updated: Apr 6, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Does a reasonable treatment approach beyond second-line exist?

Bernard Escudier1

  • 1Institut Gustave Roussy, Villejuif, France.

EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]
|July 29, 2015
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Related Experiment Videos

Last Updated: Apr 6, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K